,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2018-06-25 04:44:00,"Chicago, IL - June 25, 2018 - Zacks.com announces the list of stocks featured in the Analyst Blog.",0.018332526087760925,0.008541151881217957,0.9731263518333435,neutral,0.009791374206542969
1,2018-06-25 04:44:00,Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.,0.021041298285126686,0.011407552286982536,0.9675511121749878,neutral,0.00963374599814415
2,2018-06-25 04:44:00,"Stocks recently featured in the blog include Procter & Gamble PG , AbbVie ABBV , IBM IBM , McDonald's MCD and General Electric GE .",0.02108977921307087,0.01088885311037302,0.9680213928222656,neutral,0.01020092610269785
3,2018-06-25 04:44:00,"Today, Zacks is promoting its ''Buy'' stock recommendations.",0.3684377670288086,0.010614300146698952,0.6209479570388794,neutral,0.3578234612941742
4,2018-06-25 04:44:00,Get #1Stock of the Day pick for free.,0.0864095613360405,0.03249066323041916,0.8810997605323792,neutral,0.05391889810562134
5,2018-06-25 04:44:00,"Here are highlights from Friday's Analyst Blog:

The Zacks Research Daily presents the best research output of our analyst team.",0.2284756302833557,0.009567669592797756,0.7619567513465881,neutral,0.21890796720981598
6,2018-06-25 04:44:00,"Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble, AbbVie and IBM.",0.04565747082233429,0.00847074668854475,0.9458718299865723,neutral,0.037186723202466965
7,2018-06-25 04:44:00,These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.,0.054846275597810745,0.007339245639741421,0.937814474105835,neutral,0.04750702902674675
8,2018-06-25 04:44:00,"You can see all of today's research reports here >>>

Procter & Gamble 's shares have underperformed the Zacks Soap and Cleaning Materials industry year to date (-16.8% vs. -11.5%).",0.17739655077457428,0.7982822060585022,0.02432125434279442,negative,-0.6208856701850891
9,2018-06-25 04:44:00,"The Zacks analyst thinks Procter & Gamble has been benefiting from higher demand for skincare products, along with fabric and home care products.",0.9441626071929932,0.016083890572190285,0.0397535040974617,positive,0.9280787110328674
10,2018-06-25 04:44:00,"Further, the company boasts an impressive earnings surprise history, which continued in third-quarter fiscal 2018.",0.9363603591918945,0.015158639289438725,0.04848100617527962,positive,0.9212017059326172
11,2018-06-25 04:44:00,"Also, results improved year over year.",0.9534383416175842,0.01920127682387829,0.027360428124666214,positive,0.9342370629310608
12,2018-06-25 04:44:00,"While bottom-line results were aided by productivity cost savings, top line was driven by organic sales growth and higher volumes.",0.9515470862388611,0.019083745777606964,0.02936909906566143,positive,0.9324633479118347
13,2018-06-25 04:44:00,"Management remains focused on product improvement, packaging and marketing initiatives, and productivity cost-savings plan.",0.08995126932859421,0.005973464343696833,0.9040752649307251,neutral,0.08397780358791351
14,2018-06-25 04:44:00,"The company is witnessing strained margins owing to increased commodity costs, adverse geographic and product mix as well as unfavorable pricing impacts and product reinvestments.",0.018422860652208328,0.9636552929878235,0.017921794205904007,negative,-0.9452324509620667
15,2018-06-25 04:44:00,"Also, slower global market growth along with softness across Baby, Feminine and Family Care segment remains concerns.",0.03792312741279602,0.8504762053489685,0.11160071194171906,negative,-0.8125530481338501
16,2018-06-25 04:44:00,(You can read the full research report on Procter & Gamble here >>> ).,0.013788774609565735,0.010992237366735935,0.9752189517021179,neutral,0.0027965372428297997
17,2018-06-25 04:44:00,"Shares of AbbVie have lost -1.2% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry, which has declined -5.1% over the same period.",0.01800224557518959,0.97312331199646,0.008874425664544106,negative,-0.9551210403442383
18,2018-06-25 04:44:00,"AbbVie's key drug, Humira is performing well based on strong demand trends despite new competition.",0.9490495324134827,0.01717436872422695,0.03377602994441986,positive,0.9318751692771912
19,2018-06-25 04:44:00,"Moreover, Imbruvica has multibillion-dollar potential and AbbVie is exploring the possibility of label expansion into solid tumors and autoimmune diseases.",0.7418853044509888,0.010249016806483269,0.24786566197872162,positive,0.7316362857818604
20,2018-06-25 04:44:00,Mavyret's launch has been stronger than expected.,0.9522221684455872,0.02049923501908779,0.02727855183184147,positive,0.9317229390144348
21,2018-06-25 04:44:00,Mavyret has become a major growth driver for AbbVie in a short time on the market.,0.9199695587158203,0.012768492102622986,0.06726192682981491,positive,0.9072010517120361
22,2018-06-25 04:44:00,AbbVie has an impressive late-stage pipeline with label expansions for both new and existing products expected over the next few years.,0.8751019835472107,0.010924117639660835,0.11397386342287064,positive,0.8641778826713562
23,2018-06-25 04:44:00,Several pivotal data readouts and regulatory milestones are expected in 2018.,0.3562658429145813,0.015462944284081459,0.628271222114563,neutral,0.3408029079437256
24,2018-06-25 04:44:00,Promising data from several pivotal studies and settlement of its second Humira patent dispute with Biogen are other tailwinds.,0.5928283333778381,0.05819500982761383,0.34897667169570923,positive,0.5346333384513855
25,2018-06-25 04:44:00,"However, Viekira's sales continue to be hurt by intensifying competition.",0.020402133464813232,0.9611741304397583,0.018423741683363914,negative,-0.9407719969749451
26,2018-06-25 04:44:00,"Also, potential long-term competition to Humira is a concern.",0.060718197375535965,0.13803915679454803,0.8012425899505615,neutral,-0.07732096314430237
27,2018-06-25 04:44:00,(You can read the full research report on AbbVie here >>> ).,0.013080944307148457,0.013050665147602558,0.9738683700561523,neutral,3.0279159545898438e-05
28,2018-06-25 04:44:00,"IBM 's shares have underperformed the broader market on a year-to-date basis, losing -8% vs. the S&P 500's +3% gain.",0.029383808374404907,0.9605487585067749,0.010067405179142952,negative,-0.9311649799346924
29,2018-06-25 04:44:00,"The Zacks analyst likes IBM's improving position in the cloud, security and analytics.",0.9428975582122803,0.015277102589607239,0.04182528704404831,positive,0.9276204705238342
30,2018-06-25 04:44:00,"Moreover, accretive acquisitions have expanded IBM's product portfolio into higher-growth segments, such as Cloud computing and Big Data.",0.938119649887085,0.01454436220228672,0.04733595624566078,positive,0.9235752820968628
31,2018-06-25 04:44:00,"Further, expanding footprint in the rapidly growing blockchain market is positive.",0.9238269925117493,0.014423603191971779,0.061749376356601715,positive,0.909403383731842
32,2018-06-25 04:44:00,The expanded partnership with Red Hat bodes well for the company in the long haul.,0.9458147883415222,0.01536925695836544,0.03881590813398361,positive,0.9304455518722534
33,2018-06-25 04:44:00,Oniqua buyout will add asset optimization capabilities IoT based capabilities to aid IBM's Maximo.,0.9056328535079956,0.012927376665174961,0.0814398005604744,positive,0.892705500125885
34,2018-06-25 04:44:00,IBM has positive record of earnings surprises in recent quarters.,0.9432170987129211,0.02508958987891674,0.03169332817196846,positive,0.9181275367736816
35,2018-06-25 04:44:00,"However, the strategic imperatives will take some more time to report meaningful growth and offset weakness in the traditional business.",0.9324612617492676,0.015632839873433113,0.05190589278936386,positive,0.9168283939361572
36,2018-06-25 04:44:00,IBM's ongoing heavily time-consuming business model transition to cloud continues to hurt the stock.,0.022683726623654366,0.960434079170227,0.01688222773373127,negative,-0.9377503395080566
37,2018-06-25 04:44:00,"Additionally, intensifying competition is a major concern.",0.04956046864390373,0.023344861343503,0.9270946383476257,neutral,0.026215607300400734
38,2018-06-25 04:44:00,Estimates have been stable lately ahead of the company's Q2 earnings release.,0.8336507081985474,0.03537437692284584,0.13097484409809113,positive,0.7982763051986694
39,2018-06-25 04:44:00,(You can read the full research report on IBM here >>> ).,0.014667396433651447,0.01555508654564619,0.9697775840759277,neutral,-0.0008876901119947433
40,2018-06-25 04:44:00,Other noteworthy reports we are featuring today include McDonald's and General Electric.,0.028894836083054543,0.006689257454127073,0.9644159078598022,neutral,0.022205578163266182
41,2018-06-25 04:44:00,Looking for Stocks with Skyrocketing Upside?,0.09469357132911682,0.09826507419347763,0.807041347026825,neutral,-0.0035715028643608093
42,2018-06-25 04:44:00,Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.,0.41462862491607666,0.01087752915918827,0.5744938254356384,neutral,0.40375110507011414
43,2018-06-25 04:44:00,"Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021.",0.8838319182395935,0.03136736899614334,0.08480073511600494,positive,0.8524645566940308
44,2018-06-25 04:44:00,"Early investors stand to make a killing, but you have to be ready to act and know just where to look.",0.19955629110336304,0.018484661355614662,0.781959056854248,neutral,0.18107162415981293
45,2018-06-25 04:44:00,"See the pot trades we're targeting>>

Today, Zacks is promoting its ''Buy'' stock recommendations.",0.37482255697250366,0.011659106239676476,0.6135183572769165,neutral,0.36316344141960144
46,2018-06-25 04:44:00,Get #1 Stock of the Day pick for free .,0.2226315140724182,0.024793583899736404,0.7525749206542969,neutral,0.1978379338979721
47,2018-06-25 04:44:00,Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.,0.06386703997850418,0.004654404241591692,0.9314785599708557,neutral,0.059212636202573776
48,2018-06-25 04:44:00,"Continuous coverage is provided for a universe of 1,150 publicly traded stocks.",0.036364275962114334,0.004866600502282381,0.9587691426277161,neutral,0.03149767592549324
49,2018-06-25 04:44:00,Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance.,0.054108913987874985,0.005191051866859198,0.9407000541687012,neutral,0.04891786351799965
50,2018-06-25 04:44:00,Recommendations and target prices are six-month time horizons.,0.013092893175780773,0.007127966266125441,0.9797791242599487,neutral,0.0059649269096553326
51,2018-06-25 04:44:00,"Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar.",0.044983625411987305,0.5624399185180664,0.3925764560699463,negative,-0.5174562931060791
52,2018-06-25 04:44:00,They're virtually unknown to the general public.,0.035764459520578384,0.0785161554813385,0.885719358921051,neutral,-0.04275169596076012
53,2018-06-25 04:44:00,"Yet today's 220 Zacks Rank #1 ""Strong Buys"" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015.",0.6580293774604797,0.017276067286729813,0.32469451427459717,positive,0.6407533288002014
54,2018-06-25 04:44:00,Its average gain has been a stellar +26% per year.,0.8422174453735352,0.0191669799387455,0.13861553370952606,positive,0.8230504393577576
55,2018-06-25 04:44:00,See these high-potential stocks free >>.,0.12527841329574585,0.05778927728533745,0.8169323205947876,neutral,0.0674891322851181
56,2018-06-25 04:44:00,"Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.",0.01284766010940075,0.009404126554727554,0.9777481555938721,neutral,0.003443533554673195
57,2018-06-25 04:44:00,Past performance is no guarantee of future results.,0.023727279156446457,0.008731111884117126,0.9675416350364685,neutral,0.01499616727232933
58,2018-06-25 04:44:00,Inherent in any investment is the potential for loss.,0.023265572264790535,0.09617827832698822,0.8805561661720276,neutral,-0.07291270792484283
59,2018-06-25 04:44:00,"This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security.",0.011962415650486946,0.010706594213843346,0.9773310422897339,neutral,0.0012558214366436005
60,2018-06-25 04:44:00,No recommendation or advice is being given as to whether any investment is suitable for a particular investor.,0.01822577603161335,0.008984367363154888,0.9727898240089417,neutral,0.009241408668458462
61,2018-06-25 04:44:00,"It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable.",0.020858757197856903,0.007662615738809109,0.9714785814285278,neutral,0.013196141459047794
62,2018-06-25 04:44:00,All information is current as of the date of herein and is subject to change without notice.,0.01124907098710537,0.013303965330123901,0.9754469990730286,neutral,-0.002054894343018532
63,2018-06-25 04:44:00,Any views or opinions expressed may not reflect those of the firm as a whole.,0.008276145905256271,0.021656149998307228,0.9700676798820496,neutral,-0.013380004093050957
64,2018-06-25 04:44:00,"Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities.",0.009504852816462517,0.012596068903803825,0.9778990745544434,neutral,-0.0030912160873413086
65,2018-06-25 04:44:00,These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs.,0.14585068821907043,0.02033580094575882,0.8338135480880737,neutral,0.1255148947238922
66,2018-06-25 04:44:00,These are not the returns of actual portfolios of stocks.,0.010538044385612011,0.012450686655938625,0.9770112633705139,neutral,-0.0019126422703266144
67,2018-06-25 04:44:00,The S&P 500 is an unmanaged index.,0.022511588409543037,0.0801919475197792,0.8972964882850647,neutral,-0.05768036097288132
68,2018-06-25 04:44:00,Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.,0.01078665629029274,0.015373211354017258,0.9738401174545288,neutral,-0.004586555063724518
69,2018-06-25 04:44:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
70,2018-06-25 04:44:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069374665617943,0.007019795011729002,0.9422864317893982,neutral,0.04367395117878914
71,2018-06-25 04:44:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
72,2018-06-25 04:44:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
